Clinical Trial Detail

NCT ID NCT02678572
Title Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Delcath Systems Inc.
Indications
Therapies

Dacarbazine

Ipilimumab

Melphalan

Pembrolizumab

Age Groups: adult

No variant requirements are available.